병기 2기와 3기 직장암 환자에서 수술 후 항암화학요법과 동시방사선화학요법 = Postoperative Adjuvant Chemotherapy and Concruuent Chemoradiotherapy in Patients with Rectal Cancer of Stage Ⅱ and Ⅲ

다국어 초록 (Multilingual Abstract)

Background : Postoperative adjuvant therapy has been required in patients with operable rectal cancer because of risk of recurrence after surgery. Adjuvant therapies are known to chemotherapy (CTx), radiotherapy, and concurrent chemoradiotherapy (CCRT). Purpose of our study to compare the suvival rate, recurrence rate and toxicities between postoperative adjuvant CTx and CCRT in patients with rectal cancer after surgical treatment.
Materials and Methods : This study involved 45 patients (CCRT; 15, median age; 58 years, range; 39-73) and CTx; 30, median age; 55 years, range; 36-67) with rectal cancer of stage II and III between April 2002 and May 2008. Treatment included six cycles of chemotherapy at 4-week intervals with fluorouracil 425mg/m2 and leucovorin 20mg/m2 administering continuous infusion for 24 hours during 5 days in CCRT group. Radiotherapy started on day 1 of the third chemotherapy cycle in CCRT. In CTx group, treatment included the same cycles of chemoterapy, and drug doses as in CCRT group.
Results : Disease free survival (DFS) and Overall survival (OS) for 3 years were 68.4% and 70.8% in CCRT group and 82.5% and 80.5% in CTx group, respectively (DFS; P-value 0.997, OS; P-value 0.880). Recurrence rate including local recurrence and distant metastasis were 26.7% in CCRT group and 23.3% in CTx group (p-value 0.806). Local recurrence rates were 0% in CCRT group and 16.7% in CTx group (p-value 0.094). We investigated hematologic and non-hematologic toxicites. The incidence of radiation related proctitis was 26.7% in CCRT group and 0% in CTx group. But other toxicities were not significantly different between CCRT group and CTx group.
Conclusion : DFS and OS were not different between CCRT group and CTx group in patients with rectal cancer of stage II and III. But local recurrence rate was lower in CCRT group than in CTx group. Toxicities were not differrent between CCRT group and CTx group, except the higher frequency of radiation related proctitis in CCRT group.

목차 (Table of Contents)

• 서론
• 대상 및 방법
• 대상
• 치료
• 반응평가
• 통계분석
• 결 과
• 대상 환자들의 임상적 특성
• 치료 결과
• 독성
• 고찰
• 결론
• 참고문헌

참고문헌 (Reference)

1 Kemeny N, "Role of chemotherapy in the treatment of colorectal carcinoma" 3 : 190-214, 1987

2 Lee JH, "Randomized trial of postoperative adjuvant therapy in stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: a preliminary report" 20 : 1751-1758, 2002

3 Wolmark N, "Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02" 92 : 388-396, 2000

4 Aranda E, "Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: a Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study" 9 : 727-731, 1998

5 Cafiero F, "Preliminary analysis of a randomized clinical trial of adjuvant postoperative RT vs. postoperative RT plus 5-FU and levamisole in patients with TNM stage II-III resectable rectal cancer" 75 : 80-88, 2000

6 Fountzilas G, "Postoperative radiation and concomitant bolus fluorouracil with or without additional chemotherapy with fluorouracil and high-dose leucovorin in patients with high-risk rectal cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group" 10 : 671-676, 1999

7 Fisher B, "Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01" 80 : 21-29, 1988

8 Hansen RM, "Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer" 88 : 668-674, 1996

9 Cafiero F, "P.A.R Cooperative Study Group. Randomised clinical trial of adjuvant postoperative RT vs. sequential postoperative RT plus 5-FU and levamisole in patients with stage II-III resectable rectal cancer: a final report" 83 : 140-146, 2003

10 Arbman G, "Local recurrence following total mesorectal excision for rectal cancer" 83 : 375-379, 1996

11 Glynne-Jones R, "Improving chemoradiotherapy in rectal cancer" 4 : 29-34, 2001

12 Gunderson LL, "Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis" 1785-1796, 2004

13 Pascal P, "Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer" 16 : 301-308, 1998

14 O'Connell MJ, "Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer" 15 : 246-250, 1997

15 R Gray, "Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials" 358 : 1291-1304, 2001

16 Jemal A, "Cancer statistics" 55 : 10-30, 2005

17 Wolpin BM, "Adjuvant treatment of colorectal cancer" 57 : 168-185, 2007

18 Tepper JE, "Adjuvant therapy in rectal cancer:analysis of stage, sex, and local control--final report of intergroup 0114" 20 : 1744-1750, 2002

19 Erlichman C, "A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma" 6 : 469-475, 1988